A2 Therapeutics

A2 Therapeutics is a Baylor College of Medicine spinout developing a biologic drug, A2 Therapy (A2Tx), to treat thrombosis (clotting) associated with systemic inflammation. A2Tx targets and binds to fibrin to modulate clot formation and degradation: the healthy formation and breakdown of blood clots. Fibrin deposition is a hallmark found in autopsies of patients that succumbed to conditions associated with uncontrolled clotting such as in sepsis, DIC, TBI, and COVID-19. With proof-of-concept completed in both small and large animal models, and with recent FDA guidance via the Agency's INTERACT program, A2 Therapeutics requires an additional $6.5M to execute its IND-enabling development plan. With one issued US Patent and multiple patent applications pending, A2 Therapeutics has over 60 years of regulatory and biologic drug development expertise to deliver a therapy for the $26B anti-thrombotic therapy market. A2Tx is a safe anti-thrombotic drug that does not increase bleeding.